Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Men over the age of 18 years
Histologically or cytologically confirmed adenocarcinoma prostate cancer
Metastatic disease confirmed either by a positive bone scan, or for soft tissue or visceral metastases, either by contrast-enhanced abdominal/pelvic/chest computed tomography (CT) or magnetic resonance imaging (MRI) scan
Patients diagnosed with mHSPC by the investigator under routine clinical practice, and must be judged appropriate for/decided to be treated with darolutamide plus ADT and docetaxel therapy by the investigator under routine clinical practice
ADT (GnRH agonist/antagonist or orchiectomy) before or simultaneous treatment with darolutamide
Signed informed consent
You may not be if
Participation in an investigational program with interventions outside of routine clinical practice
Contraindications according to the local marketing authorization
Previous treatment with darolutamide
Clareo Health | A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer
